VolitionRX Ltd (AMEX:VNRX)
$ 0.72 -0.0071 (-0.98%) Market Cap: 59.63 Mil Enterprise Value: 54.00 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

VolitionRX Ltd Data Insights Webinar Transcript

Oct 26, 2023 / 02:30PM GMT
Release Date Price: $0.735 (-9.35%)
Soo Romanoff
Edison Group - Moderator

Hello. I'm Soo Romanoff. I'm here with the Volition team, and we're excited to share some of their developments in early cancer detection screening.

The Volition team's prepared a video presentation, and we'll share that with you shortly. It will be followed up with Q&A with Louise Batchelor, Group Chief Marketing and Communications Officer; Jake Micallef, Chief Scientific Officer; and Dr. Andrew Retter, a leading UK-based hematologist and medical consultant to Volition. (Event Instructions)

Without further ado, let's get started.

Gael Forterre
VolitionRx Limited - Chief Commercial Officer

(video starts)

Well, good morning and good afternoon. I'm Gael Forterre, the Chief Commercial Officer of Volition. It's a pleasure to welcome you to this webinar today and to introduce you to Dr. Jake Micallef, our Chief Scientific Officer; and Dr. Andrew Retter for their presentations on the breakthrough cancer detection method.

Before the detailed science, a few words. Our mission is to save

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot